TY - JOUR ID - 21735 TI - Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma JO - Asia Oceania Journal of Nuclear Medicine and Biology JA - AOJNMB LA - en SN - 2322-5718 AU - Mohite, Ashish AU - Rangarajan, Venkatesh AU - Goda, Jayant AU - Chugh, Swati AU - Agrawal, Archi AU - Sengar, Manju AD - Department of Nuclear medicine and Molecular Imaging, Tata Memorial Centre, Mumbai Maharashtra, India AD - Department of Radiation Oncology, Tata Memorial Centre, Mumbai Maharashtra, India AD - Department of Haematooncology, Tata Memorial Centre, Mumbai Maharashtra, India Y1 - 2023 PY - 2023 VL - 11 IS - 2 SP - 111 EP - 121 KW - Advanced Hodgkin’s lymphoma KW - 18F-FDG PET/ CT KW - metabolic tumor parameters KW - clinicopathological parameters KW - Event Free Survival DO - 10.22038/aojnmb.2023.69260.1482 N2 - Objective(s): Advanced Hodgkin Lymphoma has a higher probability of relapse and recurrence. Classical clinicopathological parameters including the International Prognostic Score (IPS) have not been reliable in predicting prognosis or tailoring treatment.  Since FDG PET/CT is the standard of care in staging Hodgkin Lymphoma, this study attempted to evaluate the clinical utility of baseline metabolic tumor parameters in a cohort of advanced Hodgkin lymphoma (stage III and IV).Methods: Histology-proven advanced Hodgkin Patients presenting to our institute between 2012-2016 and treated with chemo-radiotherapy (ABVD / AEVD) were followed up till 2019. Quantitative PET/CT and clinicopathological parameters were used to estimate the Event Free Survival (EFS) in 100 patients. Kaplan-Meier method with log-rank test was used to compare the survival times of prognostic factors.Results: At a median follow-up of 48.83 months (IQR:33.31-63.05 months), the five-year-EFS was 81%. Of the 100 patients, 16 had relapsed (16%) and none died at the last follow-up. On Univariate analysis, among non-PET parameters bulky disease (P=0.03) and B-symptoms (P=0.04) were significant while among PET/CT parameters SUVmax (p=0.001), SUVmean (P=0.002), WBMTV2.5 (P<0.001), WBMTV41% (P<0.001), WBTLG2.5 (P<0.001) and WBTLG41% (P <0.001) predicted poorer EFS.  5-year EFS for patients with low WBMTV2.5 [<1038.3 cm3] was 89% and 35% for patients with high WBMTV2.5 [≥1038.3 cm3] (p <0.001). In a multivariate model, only WBMTV2.5 (P=0.03) independently predicted poorer EFS.Conclusion: PET-based metabolic parameter (WBMTV2.5) was able to prognosticate and complement the classical clinical prognostic factors in advanced Hodgkin Lymphoma. This parameter could have a surrogate value for prognosticating advanced Hodgkin lymphoma. Better prognostication at baseline translates to tailored or risk-modified treatment and hence higher survival. UR - https://aojnmb.mums.ac.ir/article_21735.html L1 - https://aojnmb.mums.ac.ir/article_21735_affe89cd5ac7aa48148979b5c3de7a05.pdf ER -